AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02751502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: m2 Bimanual Arm Trainer (BAT)
Description: Patients in the device group will be asked to train specific movements repeatedly with the device for 45 minutes five days a week for 6 weeks and compliance will be monitored through training logs and remotely
Study NCT02520232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination of aerobic and strength exercises
Description: Combination of aerobic and strength exercises
Study NCT01697618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
Study NCT01697618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
Study NCT02520232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching and balance exercise program
Description: Stretching and balance exercise program
Study NCT03937180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended care
Description: An interactive e-learning programme delivered through a secured web-based platform for patients and general practitioners (GPs), blended with face-to-face contacts between the involved GP and patient.
Study NCT03937180 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: General practitioners offering usual care are expected to follow the Belgian guidelines as described in the most recent online version of Anxiety, stress and sleeping problems A toolbox for general practitioners. or Sleeping pills and sedatives. How to assist your patients in the search for other solutions? which are both available in French and Dutch.
Study NCT03499028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JointCOACH
Description: Patients randomized to this group will utilize JointCOACH to communicate with their surgical team, receive information
Study NCT02868008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microsurgical resection of brain AVMs
Description: fMRI guided microsurgical resection of brain AVMs
Study NCT00720109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Given IT
Study NCT00720109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00720109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV
Study NCT00720109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT01697618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic human insulin 30
Description: Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
Study NCT01697618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic human insulin 30
Description: Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
Study NCT04096976 — intervention group
Intervention type: OTHER
Intervention: logistic regression
Description: To identify associations between factors listed in Table 1 and hospital survival, we used logistic regression
Study NCT02802267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inecalcitol
Description: vitamin D receptor agonist
Study NCT02802267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo
Study NCT02292836 — intervention group
Intervention type: OTHER
Intervention: Questionnaire testing
Description: Questionnaire testing on rosacea and non-rosacea dermatology outpatients
Study NCT00720109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT00720109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study NCT00720109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT03156387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: 2.8 W diode laser surgery were applied on high frenulum attachment and follow-up VAS scores were evaluated
Study NCT03156387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel
Description: Scalpel surgery were performed after local anesthetic administration and VAS scores were recorded.
Study NCT01617746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: 5mg od two weeks
Study NCT01617746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: 62.5mg bd two weeks
Study NCT01617746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: bd for two weeks
Study NCT03563183 — intervention group
Intervention type: OTHER
Intervention: Encoding of data collected in Zoster 006 and Zoster 022 studies
Description: Not applicable (disease epidemiology study)
Study NCT01942733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: 2-3 mg/day, once daily, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgment.
Study NCT00192634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine 200mg - Tenofovir 300mg
Description: 1 tablet once daily for 96 weeks
Study NCT00192634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir 600mg - Lamivudine 300mg
Description: 1 tablet once daily for 96 weeks
Study NCT01543633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be infused using a computer controlled delivery system running the program STANPUMP. Loss of consciousness will be defined as loss of response to auditory stimulus (button press).
Study NCT00838513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eculizumab
Description: All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
Study NCT01491984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy order: 1) MAC, 2) Levitan
Description: Laryngoscopy with MAC, then Levitan
Study NCT01491984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy order: 1) Levitan, 2) MAC
Description: Laryngoscopy with Levitan, then MAC
Study NCT05162937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-17A antibody
Description: Recombinant fully human IgG4 anti-IL-17A monoclonal antibody drug
Study NCT05162937 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IL-17A antibody
Description: Recombinant fully human IgG4 anti-IL-17A monoclonal antibody drug
Study NCT01594528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pain tests
Description: pain induction with pressure application or ischemia on the arm
Study NCT00486291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: phentermine 15mg/topiramate 100mg
Study NCT00486291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study NCT02497742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic metabolic panel
Description: Patients blood is collected in routine fashion for basic blood chemistries
Study NCT04135287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist
Description: The main objective of the study is to determine the relationship between the increase in glucose-stimulated insulin secretion and decrease in HbA1c caused by GLP-1 RA therapy in poorly controlled T2DM patients. We also will identify a cut point of an increase in beta cell function which produces a clinically meaningful decrease in HbA1c.
Study NCT04588454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-PSMA-1007 PET tracer
Description: 18F-PSMA-1007 PET/CT
Study NCT01931371 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anal Fistula Plug
Description: Surgical procedure for the treatment of anal fistula with an Anal Fistula Plug
Study NCT01931371 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endorectal Advancement Flap
Description: Surgical procedure for the treatment of anal fistula by an Advancement Mucosa Flap
Study NCT05118880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Bullying Counseling Program based on the Interpersonal Relationship Model
Description: The content of the program was created by the researcher in line with the issues that peer bullying children need support based on their bullying-related characteristics in the light of the relevant literature. Education topics prepared in this framework; 'Empathy', 'Peer Bullying', 'Anger Management' and 'Happy Friendship Relationships' were determined. The main nursing problem of the research is peer bullying. The main purpose of the Peer Bullying Counseling Program is to improve the empathy skills of the bullying child, to enable them to gain the right perspective towards bullying, to develop anger control, and to help them establish happy friendships. The content of the Peer Bullying Counseling Program; drawing, brainstorming, empathy demonstration, white paper activity, educational matching game, peer bullying demonstration, case studies, educational emotion puzzle game, anger control information video were applied using educational techniques.
Study NCT04625517 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Mammography
Description: Digital Mammography enhanced with an iodinated contrast agent
Study NCT04625517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml
Description: Injection of low osmolar contrast material during the digital mammography exam
Study NCT04346355 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tocilizumab
Description: In case of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
Study NCT04346355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: In case of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
Study NCT03961009 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kedrion IVIG 10%
Description: Kedrion intravenous immunoglobulin (IVIg) 10%
Study NCT01695759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alpha
Description: Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eritromax), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
Study NCT01695759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eprex
Description: Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eprex), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
Study NCT00950820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, Capecitabine, Panitumumab
Description: Panitumumab at a dose of 9 mg/kg BW every three weeks will be administered on day 1 of each cycle just prior to administration of chemotherapy.~The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
Study NCT00950820 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin, Capecitabine
Description: The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
Study NCT02090842 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ca-caseinate
Study NCT02090842 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Maltodextrin
Study NCT01757015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 (50µg, o.d. via SDDPI) in the morning,
Study NCT01757015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to NVA237
Description: Placebo to NVA237
Study NCT00066456 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Study NCT00066456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemosensitization/Potentiation Therapy
Study NCT00066456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT02628977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Based Sleep Health Education and Social Support
Description: Participants randomly assigned to the intervention arm will receive Obstructive Sleep Apnea education and social support from a trained Peer Educator.
Study NCT02628977 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Group
Description: Participants assigned to this arm of the study will receive standard sleep literature, providing information about OSA and access to available sleep services.
Study NCT04009382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin Exercise
Description: Subjects will participate in Baduanjin, a simple mind-body exercise, for 24 weeks.
Study NCT04009382 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Fitness Program
Description: Subjects will complete paper puzzles (Sudoku, crosswords, etc.) for 24 weeks.
Study NCT00362232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening.
Study NCT00362232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
Study NCT00362232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo: tablet of Rivaroxaban
Description: Placebo tablet of rivaroxaban administered once daily in the evening.
Study NCT00362232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo: syringes of Enoxaparin
Description: Placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
Study NCT02700841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT02700841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Given IV
Study NCT02700841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation--CD34 HSCT
Description: Undergo autologous CD34 HSCT
Study NCT02700841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation--AHSCT
Description: Undergo AHSCT
Study NCT02700841 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Blood Stem Cell Transplantation--AHSCT
Description: Undergo AHSCT
Study NCT02700841 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T Cell-Depleted Hematopoietic Stem Cell Transplantation
Description: Undergo autologous CD34 HSCT
Study NCT02700841 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid Vaccine
Description: Given IM
Study NCT02700841 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus Toxoid Vaccine
Description: Given IM
Study NCT00720109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV or SC
Study NCT00720109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT
Study NCT03816046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin A
Description: injection in hair bearing area of armpits
Study NCT00720109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT00720109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00720109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV or PO
Study NCT00720109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study NCT00720109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, PO, or IV
Study NCT02090842 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Study NCT03716154 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: Diode laser 810nm, 2W, 20sec, 20 HZ
Study NCT00607490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: Behavioral, cognitive, sex therapy and relaxation interventions administered to teach self-management skills for pain control.
Study NCT00720109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV
Study NCT00720109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IM
Study NCT00607490 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy
Description: Patient-centered talk therapy to assist participants in expressing their thoughts and feelings.
Study NCT01646229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polymyxin-B hemoperfusion
Study NCT00375752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2.5 mg.tablet.
Study NCT00375752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg.tablet.
Study NCT00375752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolendronic Acid
Description: 4 mg or an adjusted dose based on renal function in 100 ml physiologic (o.9%) normal saline, (as an intravenous infusion over no less than 15 minutes)
Study NCT01646229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study NCT02034006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: All patients received a single initial intravitreal injection of ranibizumab 0.5 mg/0.05 ml as per Committee for Human Medicinal Products (CHMP)approval. Further injections might have been required when monitoring reveals disease activity. Disease activity, defined as reduced visual acuity and/or signs of lesion activity, was evaluated based on clinical examination (BCVA, fundus), and/or optical coherence tomography (OCT), and/or fluorescein angiography (FAG). Bilateral treatment was allowed provided at least 14 days of intercurrence.
Study NCT00750269 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT 40.0 Gy
Description: SBRT delivered in 5 fractions of 8.0 Gy/fraction over 1.5 to 2 weeks for a total of 40.0 Gy
Study NCT00750269 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT 42.5 Gy
Description: SBRT delivered in 5 fractions of 8.5 Gy/fraction over 1.5 to 2 weeks for a total of 42.5 Gy
Study NCT00750269 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT 45.0 Gy
Description: SBRT delivered in 5 fractions of 9.0 Gy/fraction over 1.5 to 2 weeks for a total of 45.0 Gy
Study NCT00750269 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT 47.5 Gy
Description: SBRT delivered in 5 fractions of 9.5 Gy/fraction over 1.5 to 2 weeks for a total of 47.5 Gy
Study NCT00750269 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT 50.0 Gy
Description: SBRT delivered in 5 fractions of 10.0 Gy/fraction over 1.5 to 2 weeks for a total of 50.0 Gy
Study NCT00750269 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT 52.5 Gy
Description: SBRT delivered in 5 fractions of 10.5 Gy/fraction over 1.5 to 2 weeks for a total of 52.5 Gy
Study NCT02931773 — intervention group
Intervention type: DEVICE
Intervention: Task Force® Monitor
Description: A head up tilt test carried out with a Task Force monitoring system